Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.
The experiments aimed at evaluating the optimal parameters in the chemo-immunotherapeutic treatment of the L1210 lymphoid leukaemia grafted to [female BALB/c (H2d) X male DBA/2 (H2d)]F1 hybrid mice, hereafter referred to as CDF1 mice. In vitro irradiation of leukaemic ascites cells by X- or gamma-rays and subsequent inoculation in mice showed that optimum immunogenicity is radiation dose-dependent. Grafting mice with 10(7) leukaemic ascites cells irradiated at optimum dose (80 GyX- or gamma-rays) delays mortality of the animals when challenged later with untreated L1210 cells, but is unable to cure mice. By contrast, specific immunoprophylaxis induced by Micrococcus, complement-triggering polysaccharides or BCG and irradiated leukaemic cells was able to protect mice against grafts of 10(4) L1210 cells. The i.p. route was notably superior to the i.v. route. When mice bearing advanced L1210 tumour were treated by chemotherapy (12 mg/kg of BCNU) on Day 6.5 after grafting 10(4) L1210 cells and subsequently treated by immunotherapy, a very high percentage (up to 90%) of mice with 10(8) leukaemic cells could be cured by repeated 1mg injections of bacterium or polysaccharide, and challenge with irradiated leukaemic cells was unnecessary. Because of the high cure rate obtained, the very regular response pattern and the non-pathogenicity, the bacterium Micrococcus lysodeikticus would seem a promising new candidate for chemo-immunotherapeutic antitumour strategies.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D001500:BCG Vaccine / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007939:Leukemia L1210 / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D051379:Mice; D008837:Micrococcus / Q000276:immunology*; D009368:Neoplasm Transplantation; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine; D011135:Polysaccharides, Bacterial; D002330:Carmustine